Clinical trial
Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for…
NCT00274495 · Beth Israel Medical Center, Other · Terminated
Key facts
| NCT number | NCT00274495 |
|---|---|
| Title | Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver |
| Official title | Randomized Placebo-Control Pilot Study Evaluating the Efficacy and Safety of Rosiglitazone Combined With Pegylated Interferon Plus Ribavirin Versus Pegylated Interferon Plus Ribavirin Alone in Genotype 1 Hepatitis C With Steatosis |
| Lead sponsor | Beth Israel Medical Center, Other |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C Infection, Fatty Liver |
| Intervention type | Drug |
| Interventions | Rosiglitazone and Pegasys/Ribavirin |
| Enrollment | 30 |
| Start date | Jan 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Jan 11, 2006 |
| Last update posted | Nov 1, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: